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Background: Contrast-induced nephropathy (CIN) is a relatively frequent complication of percutaneous coronary and peripheral artery 
interventions and is associated with significant in-hospital and long term morbidity and mortality. We aim to compare the impact on major events 
of RenalGuard system (RG), continuous veno-venous Hemofiltration (CVVH) and hydration (Hy) with sodium bicarbonate plus N-acetylcysteine in 
patients with severe renal failure.
Methods: We assigned 100 consecutive not dialyzed patients with severe renal failure (eGFR ≤30 mL/min x 1.73m2 or with a baseline Serum 
Creatinine > 1.5 mg/dL, or with a CIN risk score ≥ 11) scheduled for an elective percutaneous coronary and/or peripheral interventions to a 
preventive strategy with RG (33 pts), CVVH (35 pts) or Hy (32 pts). Primary end points were In-Hospital and 1 month dialysis and MACEs, and CIN. 
Secondarily, 6-Month MACEs were recorded.
Results: In-H dialysis occurred in none of RG patients, 7 (20%) of CVVH patients vs 2 (6.3%) of Hy group (p=0.013). In-H MACEs were significantly 
less frequent in RG procedure [RG:2 (6.1%), CVVH: 13 (37.1%) and Hy: 4 (12,5%) p=0.003; OR RG vs CVVH: 0.12; CI:0.02-0.60, p=0.01]. Similar 
trends were seen at 1 and 6 month follow-up. In particular, none of RG patients died at 6 month FU, vs 9 (25,7%) CVVH patients and 2 (6,3%) 
Hydration protocol patients (p=0.002). Albeit not significant, CIN occurred less frequently in RG patients (15.2%) than CVVH (31.4%) and hydration 
protocol (25.0%) (p=0,288).
Conclusions: For the first time, RenalGuard® system, CVVH and hydration with sodium bicarbonate and N-Acetylcysteine were compared in a 
real-world population: RG demonstrated to be a safe procedure and to significantly reduce the risk of In-Hospital, 1 month and 6 month MACEs, 
compared to continuous veno-venous Hemofiltration and Hydration.
